BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

858 related articles for article (PubMed ID: 28912154)

  • 1. Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia.
    Seo J; Kritskiy O; Watson LA; Barker SJ; Dey D; Raja WK; Lin YT; Ko T; Cho S; Penney J; Silva MC; Sheridan SD; Lucente D; Gusella JF; Dickerson BC; Haggarty SJ; Tsai LH
    J Neurosci; 2017 Oct; 37(41):9917-9924. PubMed ID: 28912154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RPS23RG1 modulates tau phosphorylation and axon outgrowth through regulating p35 proteasomal degradation.
    Zhao D; Zhou Y; Huo Y; Meng J; Xiao X; Han L; Zhang X; Luo H; Can D; Sun H; Huang TY; Wang X; Zhang J; Liu FR; Xu H; Zhang YW
    Cell Death Differ; 2021 Jan; 28(1):337-348. PubMed ID: 32908202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice.
    Shukla V; Seo J; Binukumar BK; Amin ND; Reddy P; Grant P; Kuntz S; Kesavapany S; Steiner J; Mishra SK; Tsai LH; Pant HC
    J Alzheimers Dis; 2017; 56(1):335-349. PubMed ID: 28085018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV9-Mediated Cdk5 Inhibitory Peptide Reduces Hyperphosphorylated Tau and Inflammation and Ameliorates Behavioral Changes Caused by Overexpression of p25 in the Brain.
    Xu M; Huang Y; Song P; Huang Y; Huang W; Zhang HT; Hu Y
    J Alzheimers Dis; 2019; 70(2):573-585. PubMed ID: 31256130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.
    Sun LH; Ban T; Liu CD; Chen QX; Wang X; Yan ML; Hu XL; Su XL; Bao YN; Sun LL; Zhao LJ; Pei SC; Jiang XM; Zong DK; Ai J
    J Neurochem; 2015 Sep; 134(6):1139-51. PubMed ID: 26118667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of aberrant cyclin-dependent kinase 5/p25 activity in experimental traumatic brain injury.
    Yousuf MA; Tan C; Torres-Altoro MI; Lu FM; Plautz E; Zhang S; Takahashi M; Hernandez A; Kernie SG; Plattner F; Bibb JA
    J Neurochem; 2016 Jul; 138(2):317-27. PubMed ID: 26998748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synaptic deficits are rescued in the p25/Cdk5 model of neurodegeneration by the reduction of β-secretase (BACE1).
    Giusti-Rodríguez P; Gao J; Gräff J; Rei D; Soda T; Tsai LH
    J Neurosci; 2011 Nov; 31(44):15751-6. PubMed ID: 22049418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cdk5 Inhibitory Peptide Prevents Loss of Neurons and Alleviates Behavioral Changes in p25 Transgenic Mice.
    Huang Y; Huang W; Huang Y; Song P; Zhang M; Zhang HT; Pan S; Hu Y
    J Alzheimers Dis; 2020; 74(4):1231-1242. PubMed ID: 32144987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo.
    Sundaram JR; Poore CP; Sulaimee NH; Pareek T; Asad AB; Rajkumar R; Cheong WF; Wenk MR; Dawe GS; Chuang KH; Pant HC; Kesavapany S
    J Neurosci; 2013 Jan; 33(1):334-43. PubMed ID: 23283346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing.
    Wen Y; Planel E; Herman M; Figueroa HY; Wang L; Liu L; Lau LF; Yu WH; Duff KE
    J Neurosci; 2008 Mar; 28(10):2624-32. PubMed ID: 18322105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.
    Cruz JC; Tseng HC; Goldman JA; Shih H; Tsai LH
    Neuron; 2003 Oct; 40(3):471-83. PubMed ID: 14642273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of Endothelial Nitric Oxide Synthase Promotes p25 Generation and Tau Phosphorylation in a Murine Model of Alzheimer's Disease.
    Austin SA; Katusic ZS
    Circ Res; 2016 Oct; 119(10):1128-1134. PubMed ID: 27601478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation.
    Zheng YL; Amin ND; Hu YF; Rudrabhatla P; Shukla V; Kanungo J; Kesavapany S; Grant P; Albers W; Pant HC
    J Biol Chem; 2010 Oct; 285(44):34202-12. PubMed ID: 20720012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiological and pathological phosphorylation of tau by Cdk5.
    Kimura T; Ishiguro K; Hisanaga S
    Front Mol Neurosci; 2014; 7():65. PubMed ID: 25076872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy.
    Giannopoulos PF; Chu J; Sperow M; Li JG; Yu WH; Kirby LG; Abood M; Praticò D
    Biol Psychiatry; 2015 Nov; 78(10):693-701. PubMed ID: 25802082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy.
    Koller EJ; Gonzalez De La Cruz E; Machula T; Ibanez KR; Lin WL; Williams T; Riffe CJ; Ryu D; Strang KH; Liu X; Janus C; Golde TE; Dickson D; Giasson BI; Chakrabarty P
    Hum Mol Genet; 2019 Oct; 28(19):3255-3269. PubMed ID: 31261380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isomerase Pin1 stimulates dephosphorylation of tau protein at cyclin-dependent kinase (Cdk5)-dependent Alzheimer phosphorylation sites.
    Kimura T; Tsutsumi K; Taoka M; Saito T; Masuda-Suzukake M; Ishiguro K; Plattner F; Uchida T; Isobe T; Hasegawa M; Hisanaga SI
    J Biol Chem; 2013 Mar; 288(11):7968-7977. PubMed ID: 23362255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation of FTDP-17 mutant tau by cyclin-dependent kinase 5 complexed with p35, p25, or p39.
    Sakaue F; Saito T; Sato Y; Asada A; Ishiguro K; Hasegawa M; Hisanaga S
    J Biol Chem; 2005 Sep; 280(36):31522-9. PubMed ID: 15994305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calpastatin, an endogenous calpain-inhibitor protein, regulates the cleavage of the Cdk5 activator p35 to p25.
    Sato K; Minegishi S; Takano J; Plattner F; Saito T; Asada A; Kawahara H; Iwata N; Saido TC; Hisanaga S
    J Neurochem; 2011 May; 117(3):504-15. PubMed ID: 21338355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.